New medicines could provide a long-term management alternative to uterine fibroid surgeries over the next 10 years, according to a recent report from Decision Resources Group. Hysterectomies and myomectomies are the current surgical procedures for long-term management of uterine fibroids, but Decision Resources Group predicts such procedures will decrease. Effective medical alternatives to surgical procedures will include novel selective progesterone receptor modulators including Allergan and Gedeon Richter's ulipristal, Bayer's vilaprisan, and Repros' Proellex -- and gonadotropin-releasing hormone antagonists including AbbVie's elagolix, Myovant's relugolix and ObsEva's OBE-2109. Read the story.
New medicines could eliminate uterine fibroid surgeries
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.